Forbes contributors publish independent expert analyses and insights. Anisha Sircar is a journalist covering tech, finance and society. This voice experience is generated by AI. Learn more. This voice ...
Eli Lilly leads in the GLP-1 drug space with its shot-based offerings Mounjaro and Zepbound. Rival drugmaker Novo Nordisk has now introduced a pill version of its GLP-1 weight loss drug. Eli Lilly's ...
SAN FRANCISCO, Jan 12 (Reuters) - Eli Lilly's (LLY.N), opens new tab research and development head said on Monday the company will have plenty of supply to launch its much-anticipated new weight-loss ...
Eli Lilly and Nvidia, two primary drivers of the recent stock market rally, are deepening their alliance to connect silicon with biology through artificial-intelligence-powered drug development. The ...
SAN FRANCISCO, Jan 12 (Reuters) - Nvidia (NVDA.O), opens new tab and U.S. pharma giant Eli Lilly (LLY.N), opens new tab will spend $1 billion building a new joint research lab in the San Francisco Bay ...
In an interview with Bloomberg News, Eli Lilly Chief Financial Officer Lucas Montarce said that the Indiana-based pharma giant remains on track for a potential FDA approval of its obesity pill, ...
Eli Lilly (LLY) is downgraded to Sell due to overstretched valuation and intensifying competition in the weight-loss drug market. LLY's heavy reliance on high-margin US sales from Zepbound and ...
Eli Lilly (LLY 1.51%) has behaved more like a tech stock in recent years than like a pharma stock. Tech players are known to soar in the double and triple digits when the environment and corporate ...
Strive Compounding Pharmacy filed a federal antitrust lawsuit Jan. 14 against Eli Lilly and Novo Nordisk, alleging the two drugmakers used their market power to restrict access to compounded GLP-1 ...
Ahead of her 80th birthday, Dolly Parton revisited her twangy 1977 ballad, “Light of a Clear Blue Morning,” with an impressive group of friends in a new video. The clip features Lainey Wilson, Miley ...
In 2026, new obesity pills will push the booming GLP-1 market into its next chapter. Pills may serve as a more convenient — and in certain cases cheaper — alternative to today's blockbuster injections ...
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 4.5% in the afternoon session after the U.S. Food and Drug Administration (FDA) delayed its decision on the company's new oral ...